Lixte Biotechnology Holdings- Warrants (01/01/2025) (LIXTW) has a ROE of -76523.61%, below the Healthcare sector average of 29.33%.
Get informed when a big investor buys or sells
+ Follow-76523.61%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for LIXTW is -76523.61%. That is below the Healthcare sector average of 29.33%. Investors often review this figure alongside Lixte Biotechnology Holdings- Warrants (01/01/2025)'s historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, LIXTW currently prints -76523.61% for ROE, while the sector average sits near 29.33%. That is roughly 260994.8% below the sector mean. Large gaps often invite a closer look at Lixte Biotechnology Holdings- Warrants (01/01/2025)'s growth, margins, and balance sheet.
Return on Equity shows how effectively Lixte Biotechnology Holdings- Warrants (01/01/2025) converts resources into returns. At -76523.61%, LIXTW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting LIXTW's ROE (-76523.61%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Lixte Biotechnology Holdings- Warrants (01/01/2025)'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.